title: The neurokinin-1 receptor modulates the methamphetamine-induced striatal apoptosis and nitric oxide formation in mice.
abstract: In a previous study we showed that pharmacological blockade of the neurokinin-1 receptors attenuated the methamphetamine (METH)-induced toxicity of the striatal dopamine terminals. In the present study we examined the role of the neurokinin-1 receptors on the METH-induced apoptosis of some striatal neurons. To that end, we administered a single injection of METH (30 mg/kg, i.p.) to male mice. METH induced the apoptosis (terminal deoxyncleotidyl transferase-mediated dUTP nick end labeling) of approximately 20% of striatal neurons. This percentage of METH-induced apoptosis was significantly attenuated by either a single injection of the neurokinin-1 receptor antagonist, 17-beta-hydroxy-17-a-ethynyl-5-a-androstano[3,2-beta]pyrimido[1,2-a]benzimidazole (WIN-51,708) (5 mg/kg, i.p.), or the ablation of the striatal interneurons expressing the neurokinin-1 receptors (cholinergic and somatostatin) with the selective neurotoxin [Sar(9),Met(O(2))(11)] substance P-saporin. Next we assessed the levels of striatal 3-nitrotyrosine (3-NT) by HPLC and immunohistochemistry. METH increased the levels of striatal 3-NT and this increase was attenuated by pre-treatment with WIN-51,708. Our data support the hypothesis that METH-induced striatal apoptosis occurs via a mechanism involving the neurokinin-1 receptors and the activation of nitric oxide synthesis. Our findings are relevant for the treatment of METH abuse and may be relevant to certain neurological disorders involving the dopaminergic circuitry of the basal ganglia.
authors.affiliation: Department of Biological Sciences, Hunter College of the City University of New York, New York, New York, USA.
authors.forename: Judy
authors.initials: J
authors.lastname: Zhu
authors.forename: Wenjing
authors.initials: W
authors.lastname: Xu
authors.forename: Jing
authors.initials: J
authors.lastname: Wang
authors.forename: Syed F
authors.initials: SF
authors.lastname: Ali
authors.forename: Jesus A
authors.initials: JA
authors.lastname: Angulo
mesh_terms: D000704:Analysis of Variance; D000731:Androstanes / Q000494:pharmacology; D000818:Animals; D017209:Apoptosis / Q000187:drug effects*; D001562:Benzimidazoles / Q000494:pharmacology; D001831:Body Temperature / Q000187:drug effects; D000697:Central Nervous System Stimulants / Q000494:pharmacology*; D002851:Chromatography, High Pressure Liquid / Q000379:methods; D003342:Corpus Striatum / Q000187:drug effects* / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D004563:Electrochemistry / Q000379:methods; D000922:Immunotoxins / Q000494:pharmacology; D020287:In Situ Nick-End Labeling / Q000379:methods; D008297:Male; D008694:Methamphetamine / Q000494:pharmacology*; D051379:Mice; D008813:Mice, Inbred ICR; D008845:Microinjections / Q000379:methods; D009419:Nerve Tissue Proteins / Q000378:metabolism; D064729:Neurokinin-1 Receptor Antagonists; D009569:Nitric Oxide / Q000378:metabolism*; D018040:Receptors, Neurokinin-1 / Q000378:metabolism*; D054789:Ribosome Inactivating Proteins, Type 1 / Q000494:pharmacology; D000076985:Saporins; D013373:Substance P / Q000031:analogs & derivatives / Q000494:pharmacology; D014443:Tyrosine / Q000031:analogs & derivatives / Q000378:metabolism
chemical_list: D000731:Androstanes; D001562:Benzimidazoles; D000697:Central Nervous System Stimulants; D004338:Drug Combinations; D000922:Immunotoxins; D009419:Nerve Tissue Proteins; D064729:Neurokinin-1 Receptor Antagonists; D018040:Receptors, Neurokinin-1; D054789:Ribosome Inactivating Proteins, Type 1; C086111:WIN 51708; C062618:substance P, Sar(9)-Met(O2)(11)-; D009569:Nitric Oxide; D013373:Substance P; C002744:3-nitrotyrosine; D014443:Tyrosine; D008694:Methamphetamine; D000076985:Saporins
references.citation: Nat Med. 1996 Jun;2(6):699-703
references.pmid: 8640565
references.citation: J Neurochem. 2004 Jan;88(1):114-23
references.pmid: 14675155
references.citation: J Pharmacol Exp Ther. 1986 Sep;238(3):932-7
references.pmid: 2943891
references.citation: Eur J Pharmacol. 1995 Sep 25;284(3):231-9
references.pmid: 8666004
references.citation: J Chem Neuroanat. 1996 Jun;10(3-4):179-90
references.pmid: 8811421
references.citation: Neuroscience. 2001;102(4):843-51
references.pmid: 11182247
references.citation: Synapse. 1998 Dec;30(4):433-45
references.pmid: 9826235
references.citation: J Pharmacol Exp Ther. 1991 Feb;256(2):506-12
references.pmid: 1671596
references.citation: J Pharmacol Exp Ther. 2004 Oct;311(1):1-7
references.pmid: 15163680
references.citation: J Pharmacol Exp Ther. 1994 Aug;270(2):741-51
references.pmid: 8071867
references.citation: Prog Brain Res. 1998;118:3-11
references.pmid: 9932430
references.citation: Neuropharmacology. 2000 Jun 8;39(8):1337-56
references.pmid: 10818251
references.citation: J Neurochem. 2001 Feb;76(3):745-9
references.pmid: 11158245
references.citation: J Neurosci. 2004 Mar 31;24(13):3436-43
references.pmid: 15056723
references.citation: J Neurosci. 1997 Sep 15;17(18):6908-17
references.pmid: 9278526
references.citation: Brain Res Brain Res Rev. 1994 Jan;19(1):1-28
references.pmid: 7909470
references.citation: Neuropharmacology. 2002 Dec;43(8):1258-68
references.pmid: 12527475
references.citation: Inflamm Res. 2006 Jun;55(6):236-40
references.pmid: 16955242
references.citation: Synapse. 2005 Jul;57(1):1-7
references.pmid: 15858838
references.citation: Trends Neurosci. 1995 Dec;18(12):527-35
references.pmid: 8638293
references.citation: Brain Res. 2005 Jul 12;1049(2):171-81
references.pmid: 16043139
references.citation: Neuropharmacology. 1989 Oct;28(10):1145-50
references.pmid: 2554183
references.citation: J Neurosci. 1995 May;15(5 Pt 2):4102-8
references.pmid: 7751968
references.citation: Fed Proc. 1975 Aug;34(9):1823-31
references.pmid: 1097267
references.citation: Peptides. 1986 Nov-Dec;7(6):983-7
references.pmid: 2436197
references.citation: J Neurochem. 2008 Jul;106(2):696-705
references.pmid: 18410508
references.citation: J Subst Abuse Treat. 2002 Sep;23(2):151-6
references.pmid: 12220613
references.citation: Synapse. 2008 Mar;62(3):193-204
references.pmid: 18081184
references.citation: Neurology. 2000 Mar 28;54(6):1344-9
references.pmid: 10746608
references.citation: Behav Pharmacol. 2001 Nov;12(6-7):497-508
references.pmid: 11742144
references.citation: Synapse. 2005 Nov;58(2):110-21
references.pmid: 16088948
references.citation: J Pharmacol Exp Ther. 1998 Oct;287(1):107-14
references.pmid: 9765328
references.citation: J Neurochem. 1993 May;60(5):1792-9
references.pmid: 8473897
references.citation: Synapse. 1994 Jul;17(3):203-9
references.pmid: 7974204
references.citation: Proc Natl Acad Sci U S A. 1999 Apr 27;96(9):5286-91
references.pmid: 10220458
references.citation: J Pharmacol Exp Ther. 1997 Aug;282(2):834-8
references.pmid: 9262348
references.citation: Brain Res. 1982 Mar 4;235(1):93-103
references.pmid: 6145488
references.citation: Arch Biochem Biophys. 1986 May 15;247(1):1-11
references.pmid: 3010872
references.citation: Brain Res. 2004 May 8;1007(1-2):124-31
references.pmid: 15064143
references.citation: Synapse. 2011 Apr;65(4):300-8
references.pmid: 20730802
references.citation: J Neurochem. 2002 Nov;83(3):613-22
references.pmid: 12390523
references.citation: Ann N Y Acad Sci. 1992 May 11;648:317-9
references.pmid: 1637061
references.citation: J Neurosci. 1998 Mar 15;18(6):1979-86
references.pmid: 9482784
references.citation: Am J Psychiatry. 2001 Mar;158(3):377-82
references.pmid: 11229977
references.citation: J Neurosci. 2003 Sep 10;23(23):8271-80
references.pmid: 12967989
references.citation: Proc Natl Acad Sci U S A. 1998 May 12;95(10):5773-8
references.pmid: 9576960
references.citation: J Neurosci. 1995 Dec;15(12):8419-29
references.pmid: 8613773
references.citation: Science. 1998 Sep 11;281(5383):1640-5
references.pmid: 9733503
references.citation: J Pharmacol Exp Ther. 1979 Feb;208(2):203-9
references.pmid: 762652
references.citation: Synapse. 1996 Aug;23(4):328-34
references.pmid: 8855518
references.citation: J Neurochem. 1996 Oct;67(4):1770-3
references.pmid: 8858965
references.citation: J Neurochem. 2005 Apr;93(1):195-205
references.pmid: 15773919
references.citation: Neuroscience. 2006 Jun 30;140(2):607-22
references.pmid: 16650608
references.citation: Brain Res. 1980 Jul 7;193(1):153-63
references.pmid: 7378814
references.citation: Am J Psychiatry. 2001 Mar;158(3):383-9
references.pmid: 11229978
references.citation: Neurosci Lett. 1999 Dec 17;277(1):1-4
references.pmid: 10643883
references.citation: Brain Res. 1992 May 29;581(2):237-43
references.pmid: 1356579
references.citation: J Neurochem. 2001 Sep;78(5):952-9
references.pmid: 11553669
references.citation: Proc Natl Acad Sci U S A. 1999 Oct 12;96(21):12096-101
references.pmid: 10518582
references.citation: J Neurosci. 1998 Oct 15;18(20):8417-22
references.pmid: 9763484
references.citation: Brain Res. 1984 Jun 15;303(2):359-64
references.pmid: 6744029
references.citation: J Pharmacol Exp Ther. 1985 Jun;233(3):539-44
references.pmid: 2409267
references.citation: Brain Res Mol Brain Res. 2001 Sep 10;93(1):64-9
references.pmid: 11532339